



Alliance for Clinical Trials in Oncology
Friday, November 7, 2014
Loews Hotel Chicago O'Hare
4 pm – 7 pm

Lymphoma Committee Meeting Agenda

Chair: John P. Leonard, MD
Vice-Chairs: Nancy L. Bartlett, MD and Eric D. Hsi, MD

Introductory Remarks

Update from NCL Lymphoma Steering Committee

Overview of NCI LYSC Clinical Trials Planning Meeting

John P. Leonard, MD

Update on lymphoma staging and response criteria: The Lugano Classification

Bruce Cheson, MD

PET imaging as a surrogate marker for outcome

Bruce Cheson, MD

New data on minimal residual disease monitoring in lymphoma

Tom Willis, PhD, Chief Executive Officer, Sequentia, Inc.

How might we use surrogate markers in clinical trial design and in clinical practice?

Kristie Blum, MD

Update on lymphoma biology studies

Review of Alliance lymphoma translational initiatives and specimen bank resources

Eric Hsi, MD

Protocol Review

In Development	A051301	Ibrutinib with AuSCT in relapsed non-germinal center DLBCL	C. Andreadis
In Development	A051305	Phase III study of ABVD vs AAVD (with brentuximab Vedotin) in stage I/II Hodgkin lymphoma	N. Wagner-Johnston
In Development	A051306	A randomized phase II trial of rituximab, lenalidomide and ibrutinib vs. rituximab, bendamustine and ibrutinib in patients \leq 65 years of age with previously untreated mantle cell lymphoma (MCL)	K. Maddocks
Active	50801	Phase II trial of response-adapted therapy based on PET in bulky stage I/II Hodgkin lymphoma	A.LaCasce

Active	50904	Randomized phase II of ofatumumab/bendamustine vs ofatumumab/bortezomib/bendamustine in untreated FL	K. Blum
Active	A51103	Phase I study of rituximab, lenalidomide and ibrutinib in untreated follicular lymphoma	C. Ujjani
Active	CTSU	E1411: Intergroup randomized ph II 4 arm study in pts \geq 60 w/ previously untreated MCL	P. Martin
Active	51101	Myeloablative vs non-myeloablative consolidation chemotherapy for frontline CNS B cell lymphoma	T. Batchelor
Active	CTSU	NCIMET 9177: Ph II Study EPOCH +/- Rituximab in Untreated C-Myc+ DLBCL	B. Link
Active	CTSU	S1001: Ph II PET-directed therapy for limited stage DLBCL	S. Park
Active	CTSU	E1412: Phase II open label study of lenalidomide R-CHOP (R2CHOP) vs RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in patients with newly diagnosed diffuse large B cell lymphoma	K. Richards
Active, Completed Accrual	A051202	Phase I trial of rituximab, lenalidomide and idelalisib in recurrent follicular lymphoma	J. Leonard
Active, Completed Accrual	A051201	Phase I/randomized phase II trial of rituximab, lenalidomide and idelalisib in recurrent mantle cell lymphoma	S. Smith
Active, Completed Accrual	N1085	A phase I and feasibility study of everolimus (RAD001) plus R-CHOP for untreated DLBCL	P. Johnston
Active, Completed Accrual	50303	Phase III randomized trial of R-CHOP vs R-EPOCH with molecular profiling in untreated DLBCL	W. Wilson/A. Zelenetz
Active, Completed Accrual	50901	Phase II trial of ofatumumab in untreated follicular lymphoma	C. Rosenbaum
Active, Completed Accrual	S1106	R-HyperCVAD or R-bendamustine followed by autologous SCT in patients \leq age 65	T. Shea
Active, Completed Accrual	S1108	Phase II Trial of the aurora kinase a inhibitor, MLN8237, in peripheral T-Cell non-hodgkin lymphoma	S. Horwitz

New concepts/other business